Immunomedics cordially invites OSMO Members to their virtual program to introduce TRODELVYTM (sacituzumab govitecan-hziy) for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease.

Tuesday, November 4, 2020 at 6:00pm-PDT, presented by: John W. Park, MD, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, UCSF School of Medicine.

To attend, please use the Program ID 11358 and register at: www.pharmethodportal.com/Immunomedics/Register OR Contact 1-800-748-3514 or immunomedics-events@pharmethod.com